Actinium Pharmaceuticals, Inc. income statement

In fiscal 2025, Actinium Pharmaceuticals, Inc. reported revenue of $90,000, up 11.1% on the year before, operating income of −$36.2m (a -40274.4% margin) and net income of −$33.9m, or −$1.09 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Actinium Pharmaceuticals, Inc.: income statement, annual
Fiscal year	2010Dec 2010	2011Dec 2011	2021Dec 2021	2022Dec 2022	2023Dec 2023	2025Dec 2025
Revenue	0	0	1	1	0	0
Cost of revenue	—	—	1	—	—	—
Gross profit	0	0	0	—	—	—
Research and development	—	0	18	23	39	21
General and administrative	—	3	8	12	13	15
Operating income	−0	−3	−25	−34	−52	−36
Interest expense	−0	−0	—	—	—	—
Net interest income	—	—	0	1	3	—
Income tax	−0	0	—	—	—	—
Net income	−0	−3	−25	−33	−49	−34
Diluted EPS	$0.01	−$129.00	−$1.20	−$1.37	−$1.83	−$1.09
Diluted shares (average)	—	—	21m	24m	27m	31m
EBITDA	—	−3	−24	−33	−52	−36

US$ millions unless shown otherwise. Fiscal quarters.

Actinium Pharmaceuticals, Inc.: income statement, quarterly
Quarter	2021 Q4Dec 2021	2022 Q1Mar 2022	2022 Q2Jun 2022	2022 Q3Sept 2022	2022 Q4Dec 2022	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q2Jun 2026
Revenue	0	1	0	0	0	0	0	35
Research and development	5	4	5	7	7	4	4	5
General and administrative	3	2	3	3	4	2	2	2
Operating income	−8	−5	−8	−10	−11	−6	−6	28
Net interest income	0	0	0	0	1	—	—	—
Net income	−8	−5	−8	−9	−11	−5	−6	28
Diluted EPS	−$0.36	−$0.23	−$0.33	−$0.38	−$0.43	−$0.16	−$0.19	$0.89
EBITDA	−8	−5	−8	−10	−11	−5	−7	28

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: ATNM vs STTK ATNM vs MNOV ATNM vs LGVN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Actinium Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Actinium Pharmaceuticals, Inc.